Questions about cancer? Freephone 1800 200 700 Irish Cancer Society Nurseline

About this trial

The primary objective of the trial is to investigate whether weekly chemotherapy with bevacizumab extends the time until ovarian cancer relapses and whether women who receive this treatment combination live longer compared to standard chemotherapy or weekly chemotherapy alone.

Patients are randomly assigned to one of the three groups:
– Arm B1 (3-weekly chemotherapy plus bevacizumab): carboplatin, paclitaxel and bevacizumab once every 3 weeks for a total of 18 weeks (6 cycles) followed by bevacizumab alone every 3 weeks for an additional 36 weeks (12 cycles)
– Arm B2 (weekly chemotherapy): carboplatin once every 3 weeks and paclitaxel once a week (at a lower dose) for a total of 18 weeks (6 cycles)
– Arm B3 (weekly chemotherapy plus bevacizumab): carboplatin and bevacizumab once every 3 weeks plus paclitaxel once a week (at a lower dose) for a total of 18 weeks (6 cycles) followed by bevacizumab alone every 3 weeks for an additional 36 weeks (12 cycles)

Patient Profile

Patients with newly diagnosed histoloically confirmed high risk advanced (stage III-IV) ovarian, fallopian tube and primary peritoneal cancer.

Where’s this trial being run?

Bon Secours Cork, St James’s Hospital, University Hospital Galway, University Hospital Waterford, Mater Misericordiae University Hospital, and Mater Private Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.

Summary Data

Name: ICON8B
Number: 11-29
Full Title:

A Phase III randomised trial investigating the combination of dose-fractionated chemotherapy and bevacizumab compared to either strategy alone for first-line treatment of women with newly diagnosed high-risk stage III-IV epithelial ovarian, fallopian tube or primary peritoneal cancer.

Principal Investigator: Dr Dearbhaile O'Donnell (St James's Hospital)
Type: Collaborative
Sponsor:

MRC

Recruitment Started: Global: September 2015
Ireland: September 2015
Global Recruitment Target: 1170
Ireland Recruitment Target: 30